Synapse - Works

Results (2639)

Concordance between immunohistochemistry and gene expression profiling subtyping for diffuse large B‐cell lymphoma in the phase 3 PHOENIX trial

Meeting Abstract

Balasubramanian, S.; Wang, S.; Major, C.; Hodkinson, B.; Schaffer, M.; Sehn, L. H.; Johnson, P.; Zinzani, P. L.; Carey, J.; Liu, G.; more...
Hematological Oncology (2019)

Fulltext@MSK | Save

Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B‐cell lymphoma: Efficacy and safety from the phase 2 CheckMate 436 study

Meeting Abstract

Zinzani, P. L.; Santoro, A.; Gritti, G.; Brice, P.; Barr, P. M.; Kuruvilla, J.; Cunningham, D.; Kline, J.; Johnson, N. A.; Mehta‐Shah, N. A.; more...
Hematological Oncology (2019)

Fulltext@MSK | Save

Analysis of clinical determinants driving safety and efficacy of camidanlumab tesirine (ADCT‐301, Cami) in relapsed/refractory (R/R) classical Hodgkin lymphoma (CHL)

Meeting Abstract

Collins, G.; Horwitz, S.; Hamadani, M.; Samaniego, F.; Spira, A.; Caimi, P.; Davies, A.; Menne, T.; Fields, P.; Cruz, H.; more...
Hematological Oncology (2019)

Fulltext@MSK | Save

Efficacy and safety of obinutuzumab + lenalidomide + atezolizumab in patients with relapsed or refractory follicular lymphoma: Primary analysis of a phase 1b/2 trial

Meeting Abstract

Morschhauser, F.; Ghosh, N.; Lossos, I.; Palomba, M. L.; Mehta, A.; Casasnovas, O.; Stevens, D.; Chitra, S.; Knapp, A.; Nielsen, T.; more...
Hematological Oncology (2019)

Fulltext@MSK | Save

Phase I/II study of umbralisib (TGR‐1202) in combination with ublituximab (TG‐1101) and pembrolizumab in patients with REL/REF CLL and Richter's transformation

Meeting Abstract

Mato, A. R.; Svoboda, J.; Luning Prak, E. T.; Schuster, S. J.; Tsao, P. Y.; Dorsey, C.; Sarmasti, L. M.; Becker, P. S.; Brander, D. M.; Nasta, S.; more...
Hematological Oncology (2019)

Fulltext@MSK | Save

Risk of breast implant associated anaplastic large cell lymphoma (BIA‐ALCL) in a cohort of 3546 women prospectively followed after receiving textured breast implants

Meeting Abstract

Ghione, P.; Cordeiro, P. G.; Ni, A.; Hu, Q.; Ganesan, N.; Galasso, N.; Dogan, A.; Horwitz, S. M.
Hematological Oncology (2019)

Fulltext@MSK | Save

Rapid and durable responses with the SYK/JAK inhibitor cerdulatinib in a phase 2 study in relapsed/refractory follicular lymphoma - alone or in combination with rituximab

Meeting Abstract

Smith, S. D.; Munoz, J.; Stevens, D. A.; Smith, S. M.; Feldman, T. A.; Ye, J. C.; de Vos, S.; Hess, B. T.; Miller, C. B.; Khatcheressian, J. L.; more...
Hematological Oncology (2019)

Fulltext@MSK | Save

Duvelisib, an oral dual PI3K‐δ,γ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T‐cell lymphoma: Rationale for the phase 2 PRIMO trial

Meeting Abstract

Horwitz, S. M.; Foss, F. M.; Porcu, P.; Moskowitz, A.; Mehta‐Shah, N.; Jacobsen, E.; Khodadoust, M. S.; Kim, Y. H.; Weinstock, D.; Lustgarten, S.; more...
Hematological Oncology (2019)

Fulltext@MSK | Save

Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma

Journal Article

Younes, A.; Sehn, L. H.; Johnson, P.; Zinzani, P. L.; Hong, X.; Zhu, J.; Patti, C.; Belada, D.; Samoilova, O.; Suh, C.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Treatment of Rosai–Dorfman disease with oral bexarotene: A case series

Journal Article

Geller, S.; Busam, K.; Hamlin, P. A.; Moskowitz, A. J.; Horwitz, S. M.; Myskowski, P. L.
Journal of Dermatological Treatment (2019)

Fulltext@MSK | Save